Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.45 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | HTR2B | P41595 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.44 |
| ▸ | DRD1 | P21728 | 4/20 | 0.44 |
| ▸ | DRD5 | P21918 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.44 |
| ▸ | HRH1 | P35367 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963314 | 0.93 | HTR2A (0.44) | DRD2DRD3SLC6A2SLC6A4HTR2A | |
| SCHEMBL7225736 | 0.89 | HTR2A (0.42) | DRD2DRD3HTR2AHTR2BHTR7 | |
| SCHEMBL7234932 | 0.81 | DRD2 (0.42) | DRD2DRD3HTR7SIGMAR1CYP2D6 | |
| SCHEMBL6963309 | 0.77 | CACNA1G (0.41) | DRD2HTR2AHTR2BHTR1AHSD11B1 | |
| SCHEMBL6197260 | 0.77 | ADRA1A (0.42) | DRD2DRD3HTR2AHTR1AHTR7 | |
| SCHEMBL6969864 | 0.76 | HTR7 (0.40) | DRD2DRD3HTR7SIGMAR1CYP2D6 | |
| SCHEMBL6198870 | 0.75 | DRD2 (0.48) | DRD2DRD3SLC6A2SLC6A4HTR2A | |
| SCHEMBL7245716 | 0.72 | CCR1 (0.54) | DRD2SIGMAR1CCR1ADRA2ACYP2D6 | |
| SCHEMBL7234672 | 0.71 | DRD2 (0.59) | DRD2DRD3HTR1ASIGMAR1DRD4 | |
| SCHEMBL7244327 | 0.71 | HSD17B10 (0.62) | SIGMAR1LMNACCR1MEN1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| EP-1021185-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | DRD2 1498/4885DRD3 1913/4885SLC6A2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.